Cibc World Market Inc. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 450.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,213 shares of the company’s stock after buying an additional 9,994 shares during the quarter. Cibc World Market Inc.’s holdings in IDEXX Laboratories were worth $6,378,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently modified their holdings of the company. Banco Santander S.A. boosted its position in shares of IDEXX Laboratories by 4.5% in the third quarter. Banco Santander S.A. now owns 3,549 shares of the company’s stock valued at $1,853,000 after acquiring an additional 152 shares during the period. Teachers Retirement System of The State of Kentucky lifted its position in IDEXX Laboratories by 23.3% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 19,848 shares of the company’s stock valued at $10,363,000 after purchasing an additional 3,747 shares during the period. Intech Investment Management LLC boosted its holdings in shares of IDEXX Laboratories by 188.0% in the third quarter. Intech Investment Management LLC now owns 30,224 shares of the company’s stock worth $15,783,000 after buying an additional 19,731 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in IDEXX Laboratories by 22.5% during the third quarter. Hantz Financial Services Inc. now owns 11,305 shares of the company’s stock valued at $5,903,000 after purchasing an additional 2,074 shares during the period. Finally, Ground Swell Capital LLC bought a new stake in IDEXX Laboratories during the 3rd quarter valued at approximately $209,000. 87.84% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at IDEXX Laboratories
In related news, EVP Michael Lane sold 3,979 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total value of $2,740,098.56. Following the completion of the transaction, the executive vice president owned 4,076 shares in the company, valued at $2,806,896.64. This trade represents a 49.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Mazelsky sold 25,140 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the sale, the insider directly owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This represents a 23.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 41,428 shares of company stock worth $28,567,934. 0.79% of the stock is owned by insiders.
IDEXX Laboratories Stock Performance
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. IDEXX Laboratories’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period last year, the firm posted $3.22 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on IDXX. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research report on Friday, October 16th. They set a “buy” rating and a $740.00 price objective for the company. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Seven investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $717.27.
Check Out Our Latest Analysis on IDEXX Laboratories
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Further Reading
- Five stocks we like better than IDEXX Laboratories
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
